drugset / Trial / NCT06811246

A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058)

NCT06811246

Phase 1 Completed 20 enrolled Merck Sharp & Dohme LLC
NaSingle-groupOpen-labelBasic science

Summary

The goal of this study is to learn what happens to the medication islatravir (ISL), in a healthy person's body over time--called a pharmacokinetic (PK) study. Researchers want to compare the amount of islatravir in the blood when it is taken alone as a single dose and when it is taken with multiple doses of another medication called lamivudine (3TC).

Timeline

Start
2024-02-07
Primary completion
2024-07-14
Completion
2024-07-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Islatravir Other / unclassified Oral
Subject Lamivudine Other / unclassified Oral

Indications

No indication recorded.